相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
Hua Sun et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels
Ekaterina Chernogubova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Maxime Denis et al.
CIRCULATION (2012)
Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
Payal Kohli et al.
CLINICAL CARDIOLOGY (2012)
Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
Zuhier Awan et al.
CLINICAL CHEMISTRY (2012)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The PCSK9 decade
Gilles Lambert et al.
JOURNAL OF LIPID RESEARCH (2012)
EFFECTS OF AMG 145, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST PCSK9, ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN SUBJECTS TAKING STATINS: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING MULTIPLE-DOSE STUDY
Clapton Dias et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
被撤回的出版物: Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial (Retracted article. See vol. 61, pg. 1751, 2013)
Roeland Huijgen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
Marie W. Lindholm et al.
MOLECULAR THERAPY (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia Focus on Therapeutic Implications
Michel Farnier
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2011)
Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients
Edward J. Mills et al.
EUROPEAN HEART JOURNAL (2011)
PCSK9: an emerging target for treatment of hypercholesterolemia
Christopher J. Duff et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9
Brandon Ason et al.
JOURNAL OF LIPID RESEARCH (2011)
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
Robert J. Konrad et al.
LIPIDS IN HEALTH AND DISEASE (2011)
Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
G. Tibolla et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2011)
PCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease 3 Independent Studies and Meta-Analyses
Marianne Benn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
Bertrand Cariou et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
Vivienne M. Homer et al.
ATHEROSCLEROSIS (2008)
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Edward J. Mills et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Abetalipoproteinemia: two case reports and literature review
Rola Zamel et al.
ORPHANET JOURNAL OF RARE DISEASES (2008)
Serum proprotein convertase subtilisin Kexin type 9 is correlated directly with serum LDL cholesterol
William E. Alborn et al.
CLINICAL CHEMISTRY (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Christopher P. Cannon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Effect of mutations in the PCSK9 gene on the cell surface LDL receptors
J Cameron et al.
HUMAN MOLECULAR GENETICS (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
P Costet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene - Long-term follow-up and treatment response
RP Naoumova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia
RR Sankatsing et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Fatty liver in familial hypobetalipoproteinemia:: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity
T Tanoli et al.
JOURNAL OF LIPID RESEARCH (2004)
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
MR Law et al.
BRITISH MEDICAL JOURNAL (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis
G Schonfeld et al.
JOURNAL OF LIPID RESEARCH (2003)